Cheniere Energy vs Novavax Inc — how do they compare? Cheniere Energy trades at $278.18 (market cap $57.39B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Cheniere Energy is far larger — about 31.5× Novavax Inc's market cap, and Cheniere Energy pays a 0.8% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 10 Days and Novavax Inc for 59 Days on average.
| LNG | NVAX | |
|---|---|---|
Market Cap | $57.39B | $1.82B |
Volume | 1,215,835 | 6,198,505 |
Sector | Energy | Health |
52-Week High | $296.91 | $12.56 |
52-Week Low | $188.83 | $6.22 |
Typical Hold Time | 10 Days | 59 Days |
Enterprise Value | $82.85B | $1.39B |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →